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Importantly, these two signaling pathways converge on protein phosphatase inhibitor-1 (I-1), a key regulator of PP1 activity. Since PP1 opposes PKA signaling in the heart by dephosphorylating targets such as phospholamban, the ryanodine receptor, and troponin I, the regulatory role played by I-1 has been a major research focus. On phosphorylation of I-1 by PKA at Thr35, I-1 potently inhibits PP1, allowing PKA phosphorylation to propagate and increase cardiac contractility in an unopposed manner (6) . Indeed, chronic inhibition of PP1 by a constitutively active form of I-1 (AA 1-65, T35D) resulted in tremendous gains in contractility (15) . Although the role of inhibitor-1 as a PKA-stimulated inhibitor of PP1 has been well characterized, the functional consequence of phosphorylation of this protein at other sites is still a focus of investigation. Recently, it was found that I-1 is phosphorylated in cardiac muscle at Ser67 by PKC-␣, resulting in an indirect effect in the regulation of sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA)2a pump (4) , but the precise mechanism involved in this signaling pathway is not yet fully understood. Evidence supports the concept that phosphorylation of I-1 by PKC-␣ leads to an increase in PP1 activity (4) . Accordingly, our recent studies (16) identified a new in vitro PKC-␣ phosphorylation site in human I-1 at Thr75, which caused a direct increase in PP1 activity and depressed myocyte mechanical function.
Elucidating the interplay between these two newly identified phosphorylation sites on I-1 function and PP1 activity is of great importance, since PP1 activity appears to be a fundamental determinant of cardiac performance. The role of I-1 in the heart becomes especially salient in the context of heart failure, as evidenced by studies of several animal models in which increases in PP1 activity similar to those observed in human failing hearts result in severe cardiac decompensation, failure, and premature death (6, 14) .
Thus, to better understand the mechanisms by which the Ser67 and Thr75 phosphorylations of I-1 regulate cardiac contractility, we have expressed constitutively phosphorylated I-1 mutants in adult cardiomyocytes. We show that prior phosphorylation of I-1 at these sites attenuates its ability to become phosphorylated by the cAMP pathway and reduces the extent to which PP1 activity is inhibited, resulting in diminished SERCA2a transport function, decreased phospholamban phosphorylation at Ser16, and cardiac contractility. These findings offer new insights into the mechanisms underlying regulation of PP1 in cardiac cells.
METHODS

Materials.
PKA catalytic subunit and cAMP were purchased from Upstate Biotechnology. The pGEX 6P-3 plasmid, glutathione Sepharose 4B, and PreScission protease were obtained from Amersham Biosciences. Quik-Change II site-directed mutagenesis kits and BL21 CodonPlus (DE3)-RIPL competent cells were obtained from Stratagene. Diacylglycerol, ampicillin, isopropyl-1-thio-␤-D-galactopyranosidase, protease inhibitor cocktail, and forskolin were obtained from Sigma-Aldrich. T4 ligase and EcoRI and NotI restriction enzymes were purchased from New England Biolabs. [␥-
32 P]ATP was obtained from Perkin Elmer. Laminin was from BD Biosciences. Phorbol 12,13-dibutyrate (PDBu) was purchased from Calbiochem. AC1 is a custom-made (Affinity Bioreagents) rabbit polyclonal affinity-purified antibody against the NH 2-terminal sequence of I-1 (residues 1-15). Anti-phospholamban and anti-glutathione S-transferase (GST) antibodies were obtained from Affinity Bioreagents. Antibody against phospholamban phosphorylated at Ser16 was purchased from Badrilla. Mouse monoclonal antibody against PP1 was from Santa Cruz Biotechnology.
Generation of I-1 recombinant proteins and I-1 adenoviruses. The human I-1 cDNA (NCBI Accession No. CK823634) was a gift from Dr. Shirish Shenolikar (Duke University, Durham, NC). I-1 cDNA was cloned into the pGEX-6P-3 plasmid and expressed as a GSTfusion protein in BL21 CodonPlus (DE3)-RIPL competent cells, as described previously (17) . Briefly, fusion proteins were purified, and the GST tag was cleaved and removed from the medium. Samples were analyzed by SDS-PAGE to estimate the extent of cleavage and protein yield after purification. Protein concentration was determined by Micro BCA assay (Pierce). The I-1(S67D/T75D) mutant was derived from the I-1 wild-type (I-1WT) sequence with site-directed mutagenesis in a stepwise fashion (Fig. 1) . Adenoviruses encoding green fluorescent protein (GFP) (Ad.GFP), I-1WT (Ad.I-1WT), or I-1 mutants I-1(S67D), I-1(T75D), or I-1(S67D/T75D) [Ad.I-1(S67D), Ad.I-1(T75D), Ad.I-1(S67D/T75D)] were generated by using the Ad-Easy XL system in Ad-293 cells. The Quik-Change Site-Directed Mutagenesis II kit (Stratagene) was used to introduce mutations into the original I-1 cDNA. The viruses were purified with the Adenovirus Mini Purification Kit (Virapur) and titered with the Adeno-X Rapid Titer Kit (Clontech), as previously described (15) (Fig. 1) .
Primary culture of rat isolated ventricular cardiomyocytes, adenovirus infection, and contractile parameter measurements. Ventricular myocytes from adult male Sprague-Dawley rats (Ϸ300 g) were isolated by collagenase digestion as previously detailed (17) . Rats were handled according to a protocol approved by the Institutional Animal Care and Use Committee at the University of Cincinnati. Plated myocytes were infected with adenoviruses at a multiplicity of infection of 500 for 2 h at 37°C in a humidified 5% CO 2 incubator. After 24 h of infection, myocyte contraction at the basal level and under forskolin (100 nM) was performed at room temperature by using a Grass S5 stimulator (0.5 Hz). Fractional shortening (FS) and maximal rates of contraction and relaxation (dL/dtmax) were calculated with a video edge motion detector (Crescent Electronics). For immunoblotting, sarcoplasmic reticulum (SR) Ca 2ϩ uptakes, and protein phosphatase activity assays, cultured infected cardiomyocytes were harvested and homogenized with a Polytron in solubilization buffer containing (mM) 50 Tris ⅐ HCl (pH 7.0), 10 NaF, 1 EDTA, 0.3 sucrose, 0.3 PMSF, and 0.5 mM DL-dithiothreitol, with protease inhibitor cocktail (1 ml/20 g tissue). NaF was omitted from the buffer for determination of protein phosphatase activity. For PKA activation, infected myocytes were treated with forskolin (100 nM) for 15 min before homogenization and subsequent Ca 2ϩ uptake or protein phosphatase activity assays. For PKC activation, cells were treated with PDBu (1.5, 2.5, and 3.5 M) for 10 min (17) before contractility was recorded.
SR Ca 2ϩ uptake in cultured rat cardiomyocytes. After 24-h infection of isolated rat cardiomyocytes, cells were harvested and homogenized at 4°C in the buffer described above. The initial rates of SR Ca 2ϩ uptake were determined in myocyte homogenates with the Millipore filtration technique and 45 CaCl2 over a range of Ca 2ϩ concentrations (pCa 5-8). Ca 2ϩ uptake into cardiomyocytes was initiated by addition of 5 mM ATP, and aliquots were filtered through a 0.45-m Millipore filter after 0, 30, 60, and 90 s to terminate the reaction, as previously detailed (17) . The specific Ca 2ϩ uptake values [maximum Ca 2ϩ uptake rate (Vmax) and EC50] were analyzed with the OriginLab 5.1 program.
Protein phosphatase activity assay. Protein phosphatase activity was assessed in infected cardiomyocyte homogenates (1 g) with the Protein Serine/Threonine Phosphatase Assay System (New England Biolabs) according to the manufacturer's instructions and as For generation of recombinant adenoviruses, the cDNAs were subcloned from the pGEX-6P-3 vector into the pShuttle-IRES-hrGFP-1 vector and inserted into the AdEasy-1 viral backbone by homologous recombination. The mutations shown were introduced into the original cDNA by site-directed mutagenesis. CMVp, cytomegalovirus promoter; GFP, green fluorescent protein; WT, wild type. described previously (16) . Okadaic acid (10 nM) was used to discern between PP1 and protein phosphatase-2A (PP2A) activities (14, 16) .
PKA in vitro phosphorylation assays. Recombinant I-1 or I-1(S67D/T75D) mutant (7 g) was phosphorylated by PKA catalytic subunit (0.1 g) at 35°C in (mM) 50 Tris ⅐ HCl (pH 7.0), 5 MgCl 2, 5 NaF, and 1 EGTA, with 1 M cAMP (included as an extra precaution although the PKA catalytic subunit was used) and 0.25 mM [␥- 32 P]ATP (0.4 Ci/nmol). After 1 h, the reactions were stopped by adding SDS sample buffer to the medium. For the control samples, cAMP and PKA were omitted from the buffer. The amount of [ 32 P]phosphate incorporated into I-1 proteins was determined by SDS-PAGE and autoradiography. Densitometric analysis of the data was conducted with ImageQuant 5.2 software.
Immunoblot analysis. Proteins were separated by 12% SDS-PAGE and transferred to nitrocellulose membranes. After 1-2 h in 5% dried milk, membranes were probed overnight at 4°C with primary antibodies. A secondary peroxidase-labeled antibody (Amersham Biosciences) was used in combination with an enhanced chemiluminescent detection system (Supersignal West Pico Chemiluminescent, Pierce) to visualize the primary antibodies. The optical density of the bands was analyzed by ImageQuant 5.2 software.
Statistics. All values are expressed as means Ϯ SE for n experiments. Comparisons were evaluated by Student's t-test for unpaired data or one-way ANOVA, as appropriate.
RESULTS
Effects of constitutively phosphorylated I-1 at Ser67 and/or
Thr75 on myocyte contractility and SR Ca 2ϩ uptake. We showed previously (16) that phosphorylation of I-1 at Thr75 by PKC-␣ induces a significant decrease in cardiomyocyte performance. Since PKC-␣ also phosphorylates Ser67 in cardiac muscle (4), we explored whether phosphorylation of this site has the same effects on myocyte contractility as phosphorylation of Thr75, and if so, whether dual-site phosphorylation may have additive or even synergistic effects. To achieve this, adult rat cardiomyocytes were infected with adenoviruses expressing I-1 wild type (Ad.I-1WT), single-site constitutively phosphorylated I-1 [Ad.I-1(S67D) or Ad.I-1(T75D)], or dual-site phosphorylated I-1 [Ad.I-1(S67D/T75D)]. An adenovirus expressing GFP (Ad.GFP) was used as control. Adenoviral infection efficiency, assessed by green fluorescence and Western blot immunodetection, indicated that the levels of wild-type or mutant I-1 expression were similar in all groups ( Fig. 2A) , whereas endogenous I-1 was undetectable in cells infected with Ad.GFP, similar to previous observations (8, 16) . Infection with Ad.I-1WT had no effects on basal contractile parameters, while expression of I-1(S67D) reduced the rates of myocyte contraction (22%) and relaxation (27%), as well as FS (25%) to a similar extent as myocytes expressing I-1(T75D) (Fig. 2B) . Although the functional performance of myocytes expressing I-1(T75D) tended to be more attenuated than those expressing I-1(S67D), the values were not significantly different. Interestingly, expression of the constitutively dual-site phosphorylated (S67D and T75D) I-1 yielded decreases in the maximal velocities of contraction and relaxation as well as FS similar to those elicited by the single mutants (Fig. 2B) . These results indicate that phosphorylation of either Ser67 or Thr75 in I-1 results in similar decreases on myocyte contractility and that simultaneous phosphorylation of both sites does not increase these inhibitory effects.
It has been previously described that PKC-␣ phosphorylates I-1 at Ser67 and Thr75 (4, 17) . Therefore, to explore whether the negative inotropic effect of I-1(S67D) or I-1(T75D) is elicited by PKC-mediated phosphorylation of I-1, myocytes expressing I-1WT or I-1(S67D/T75D) were treated with several concentrations of the PKC activator PDBu. PDBu induced a significant decrease in FS in cells expressing I-1WT, which was dose dependent (Fig. 3) . However, there was no further decrease in the contractility of myocytes infected with the I-1(67D/75D) mutant, suggesting that PKC phosphorylation of I-1 may be partially mediating the depressive effects induced by phorbol esters on cardiomyocyte contractile parameters.
The depressed contractility of the failing heart is thought to involve alterations in the SR Ca 2ϩ cycling that, at least in part, may be associated with depressed SR Ca 2ϩ uptake (19) . Consistent with this notion, we examined SERCA2a function in myocytes infected with I-1 constitutively phosphorylated at Ser67 and/or Thr75. The initial rates of Ca 2ϩ transport were measured over a wide range of Ca 2ϩ concentrations, similar to those present in vivo during relaxation and contraction. Homogenates generated from myocytes infected with adenoviruses expressing GFP, as a control, and the I-1 forms I-1WT, I-1(S67D), I-1(T75D), or I-1(S67D/T75D) were processed under conditions that restrict Ca 2ϩ uptake to SR (12) . Infection with Ad.GFP was associated with an EC 50 value of SERCA2a for Ca 2ϩ of 0.294 Ϯ 0.01 M. This value was similar to that exhibited by I-1WT-overexpressing myocytes (0.336 Ϯ 0.013 M; Fig. 2B ). However, the apparent EC 50 of SERCA2a for Ca 2ϩ was significantly increased in myocytes expressing the I-1(S67D), I-1(T75D), or I-1(S67D/T75D) mutant (0.457 Ϯ 0.012, 0.664 Ϯ 0.014, and 0.611 Ϯ 0.005 M, respectively; Fig. 2B ), similar to contractile parameters.
Effects of PKA activation on contractility in myocytes expressing phospho-Ser67 and/or phospho-Thr75 I-1. Activation of the ␤-adrenergic/cAMP pathway in the heart results in enhanced function, which may overcome the depressive effects of proteins that inhibit cardiac contractility (11) . To assess whether stimulation of this signaling pathway is capable of reversing the impaired function of myocytes expressing constitutively phosphorylated I-1 mutants, adenovirus-infected cardiomyocytes were treated with a range of forskolin concentrations from 10 nM to 1 M. Surprisingly, high doses of forskolin elicited arrhythmias in myocytes expressing constitutively phosphorylated Ser67 and/or Thr75 I-1, but not in I-1 WT-or GFP-expressing cells. Therefore, we selected 0.1 M, which appeared optimal in GFP or I-1WT-infected myocytes, as the highest forskolin concentration that induced stimulation of contractility without eliciting arrhythmias. Forskolin treatment of myocytes expressing GFP caused dramatic increases in the velocities of contraction (38%) and relaxation (51%), as well as in FS (8.5%), compared with basal levels (Fig. 4) . The increases in performance of cells expressing I-1WT were similar to the control cells (36.5%, 49%, and 15.5% for the rate of contraction, rate of relaxation, and FS, respectively). Importantly, cardiac function of myocytes infected with Ad.I-1(S67D), Ad.I-1(T75D), or Ad.I-1(S67D/T75D) also improved on forskolin treatment, but the cardiac parameters did not reach the maximal levels observed in either the Ad.I-1WT or Ad.GFP groups (Fig. 4) . However, the relative increases in the contractile parameters of the forskolin-stimulated cardiomyocytes expressing the constitutively phosphorylated I-1 mutants were similar to the increases obtained by the Ad.GFP and Ad.I-1WT infections, indicating no alterations in the upstream PKA signaling pathway. These data suggest that although cardiac contractility of myocytes expressing the phosphorylated I-1 mutants can be enhanced by forskolin treatment, the overall function remains depressed compared with controls.
Effects of PKA activation on SR Ca 2ϩ uptake in adenovirusinfected myocytes. To explore whether the impaired SERCA2a transport function observed in cardiomyocytes expressing I-1 phosphorylated at Ser67 and/or Thr75 may be reversed by activation of the cAMP signaling pathway, adenovirus-infected cells were treated with forskolin. As expected, the EC 50 values under PKA stimulation were reduced in myocytes expressing GFP, I-1WT, or I-1(S67D), I-1(T75D), or I-1(S67D/T75D). Importantly, the relative decreases were similar in all five groups, compared with their corresponding basal values (Figs. 2B and 5, A and B) . Analysis of the corresponding values of the Ca 2ϩ transport system on PKA stimulation indicated that cardiomyocytes expressing GFP or I-1WT had similar EC 50 parameters (0.17 Ϯ 0.029 and 0.147 Ϯ 0.005 M, respectively), and these were the most stimulated parameters among the five groups (Fig. 5B) . Although forskolin also decreased the EC 50 values in cardiomyocytes expressing the constitutively phosphorylated I-1 mutant at Ser67 (0.234 Ϯ 0.005 M), Thr75 (0.342 Ϯ 0.016 M), or both sites (0.334 Ϯ 0.053 M) compared with their respective basal values (Fig. 5B) , the Ca 2ϩ uptake rates remained depressed in the mutant-expressing cells compared with myocytes expressing either I-1WT or GFP (Fig.  5, A and B) . There were no statistically significant differences among the I-1 mutants' EC 50 values (Fig. 5B) . Notably, stimulation of PKA in these groups improved SR Ca 2ϩ uptake values only to the basal levels of the control cells. There were no alterations in the maximum velocities (V max ) of Ca 2ϩ uptakes among the five groups. Interestingly, phosphorylation of phospholamban, the regulator of SERCA2a function, was reduced by 35% at Ser16 in myocytes expressing the I-1 Fig. 3 . Effects of PKC activation by phorbol 12,13-dibutyrate (PDBu) on contractility of myocytes expressing I-1WT and the double I-1 mutant. FS of adenovirus-infected myocytes with I-1WT or I-1(S67D/T75D) mutant, under basal conditions or with PDBu treatment at several concentrations (1.5, 2.5, or 3.5 M) is shown; 15-20 myocytes/heart were analyzed from 3 hearts. B, basal conditions. *P Ͻ 0.05, comparison of basal vs. PDBu in I-1WT group. $P Ͻ 0.05, comparison of I-1WT vs. I-1(S67D/T75D) at basal conditions. Note that there were no significant differences between I-1WT and I-1(S67D/T75D) with PDBu treatment. mutants compared with the GFP or I-1WT groups on PKA stimulation (Fig. 5C) . Additionally, SERCA2a protein levels were similar among the five groups (Fig. 5C ). These results indicate that phosphorylation of I-1 at either Ser67 and/or Thr75 is associated with attenuated stimulation of SERCA2a transport, which may be, at least in part, due to reduced phospholamban phosphorylation at Ser16.
PP1 activity in adenovirus-infected cardiomyocytes treated with forskolin. Since PP1 is regulated by I-1, which acts as an inhibitor on PKA stimulation, it was of special interest to explore whether phosphorylation of I-1 at Ser67 and/or Thr75 may affect PP1 activity after stimulation with forskolin. The degree of total protein phosphatase inhibition after PKA stimulation was similar among the GFP and mutant I-1-infected groups. However, the myocytes expressing I-1WT exhibited a significantly higher inhibition compared with the GFP group, indicating that the endogenous levels of I-1 may be limiting and that overexpression of this molecule results in increased inhibition of PP1 activity (Fig. 6) . Accordingly, selective PP1 inhibition, assessed by using 10 nM okadaic acid as a PP2A inhibitor (14, 16) , showed that myocytes expressing 5 . Effect of PKA stimulation on the Ca 2ϩ affinity of sarcoplasmic reticulum (SR) Ca 2ϩ transport of myocytes expressing I-1 phosphorylated at Ser67 and/or Thr75. The initial rates of sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA)2a Ca 2ϩ transport were assessed in cardiomyocytes infected with Ad.GFP, Ad.I-1WT, Ad.I-1(S67D), Ad.I-1(T75D), and Ad.I-1(S67D/ T75D) with forskolin treatment. A: data were normalized to the calculated Vmax for each group and fit to a sigmoidal curve by using the OriginLab 5.1 program. Symbols represent the average of 3 independent experiments, assayed in duplicate. B: average EC50 values for each group: statistical comparisons of each group vs. GFP. C: representative blots showing phosphorylation of phospholamban (PLN) at Ser16, using phosphospecific antibodies (1:5,000; Badrilla). The same membranes were striped and probed for total PLN (1:1,000; Affinity Bioreagents) and SERCA2a (1:1,000; custom-made antibody, Affinity Bioreagents). A total of 4 independent experiments were used for statistical analysis. *P Ͻ 0.05; **P Ͻ 0.01.
I-1WT inhibited PP1 activity more potently under forskolin, compared with the GFP control. Interestingly, this increased inhibition of PP1 was not associated with any significant alterations in phospholamban phosphorylation, the EC 50 of SERCA2a (Fig. 5B ), or contractility (Fig. 4) , suggesting that maximal stimulation appears to occur by phosphorylation of the endogenous I-1 under our conditions. In contrast, the three constitutively phosphorylated I-1 mutants, I-1(S67D), I-1(T75D), and I-1(S67D/T75D), presented less inhibition of PP1, compared with either GFP control or I-1WT-infected cells. Consistent with contractility assays (Fig. 4) , the degree of PP1 inhibition in myocytes expressing the I-1 double mutant [I(S67D/T75D)] was similar to that exhibited by either I-1(S67D) or I-1(T75D), indicating that simultaneous phosphorylation of the two sites did not exhibit an additive effect in the inhibition of PP1 activity after PKA stimulation. Similar to previous observations (16), PP1 protein levels were not altered in any of the groups (data not shown).
Phosphorylation of I-1 at Ser67 and Thr75 reduces PKAdependent phosphorylation.
To better understand the mechanism by which I-1 phosphorylated at Ser67/Thr75 is a poor inhibitor of PP1 activity, we analyzed whether these phosphorylations reduce the ability of PKA to phosphorylate I-1 at Thr35. It has been reported that substitution of Thr35 on I-1 by an alanine completely abolishes I-1 phosphorylation by PKA (9) . Moreover, this mutated I-1 failed to inhibit PP1 activity, further establishing that Thr35 is the PKA site in I-1 and that it is the only site associated with phosphatase inhibitory activity. Therefore, we examined the extent of incorporation of radioactivity after PKA phosphorylation of recombinant I-1WT and I-1(S67D/T75D) proteins in the presence of [␥-32 P]ATP. As shown in Fig. 7 , phosphorylation of Thr35 in the double mutant was reduced by 29% compared with I-1WT. However, the introduction of the false amino acids in the recombinant protein may affect phosphorylation by PKA. Therefore, the inhibition of PP1 activity was compared in 1) I-1WT recombinant protein, which was first phosphorylated by PKC-␣ in vitro and subsequently phosphorylated by PKA, and 2) I-1(S67D/T75D) recombinant protein. The percentage of PP1 inhibition (12.2 Ϯ 1.7%) was similar to I-1(S67D/ T75D) protein phosphorylated by PKA (11.8 ϩ 4.5%) (data not shown), indicating that the reduced PKA phosphorylation of the mutant may not be due to the introduction of the false amino acids. Taken together, these results suggest that phosphorylation of I-1 at Ser67 and Thr75 reduces its subsequent phosphorylation by PKA, which may contribute to depressed phospholamban phosphorylation at Ser16 (Fig. 5C ), SERCA2a Ca 2ϩ transport (Fig. 5B) , and contractility (Fig. 4) on PKA stimulation.
DISCUSSION
Heart failure is a condition of multiple etiologies associated with, among others, desensitization of the ␤-adrenergic pathway in response to chronically increased sympathetic tone (5) and increased expression of the Ca 2ϩ -dependent PKC-␣ isoform (3). These initial compensatory adaptations may ultimately lead to detrimental consequences in the heart. A regu- Fig. 6 . Percentage of inhibition of protein phosphatase-1 (PP1) activities in adenovirus-infected myocytes on PKA stimulation. Total phosphatase (PP) activity was assayed in forskolin-treated myocytes lysates expressing Ad.GFP, Ad.I-1WT, Ad.I-1(S67D), Ad.I-1(T75D), and Ad.I-1(S67D/T75D). Okadaic acid (10 nM) was added to cell lysates to differentiate type 1 and 2A phosphatase activities. Bars represent the average of 3 independent myocyte lysates assayed per duplicate. *P Ͻ 0.05 represents comparison of each group vs. GFP. Fig. 7 . PKA in vitro phosphorylation of recombinant I-1WT and I-1(S67D/T75D) mutant. A: radiolabeled phosphoproteins were detected by autoradiography. B: same membrane was probed with a specific custom-made antibody for I-1 (AC1; 1:1,000). C, control samples; PKA, phosphorylated samples. C: radioactivity associated with I-1 was quantified by densitometry, corrected for background. Bars show average of 3 independent phosphorylation reactions. *P Ͻ 0.05. latory phosphoprotein that integrates both the PKA (8) and PKC-␣ (4, 16) signaling pathways is protein phosphatase inhibitor-1 (I-1). The positive effects of PKA phosphorylation of I-1 in the heart have been well documented (6, 15) , but the precise role of the PKC phosphorylation sites in I-1 and their interaction with the cAMP-dependent kinase pathway have not been delineated, and they were the focus of this study.
Several lines of evidence from human and animal models of heart failure have established that the activity of PP1 is inversely related to cardiac performance (6, 14) . Attenuation of ␤-adrenergic signaling may underlie these effects in part, since the normal balance of PKA and PP1 activities would shift in favor of PP1 in this context. Additionally, it has been postulated that the increased PP1 activity in failing hearts is associated with diminished cAMP-dependent phosphorylation and activation of I-1 (8) . Consistent with this notion, a new emerging pathway in the regulation of PP1 suggests that phosphorylation of I-1 by PKC-␣ may contribute to enhanced PP1 activity (4, 16) . Indeed, our recent study (16) , which identified Thr75 as a new PKC-␣ site in I-1, showed that T75D I-1 recombinant protein induced an increased of PP1 activity. Accordingly, we found that constitutive phosphorylation of I-1 at Ser67 and/or Thr75 significantly reduces the extent to which PP1 becomes inhibited after PKA stimulation in cardiomyocytes. Importantly, contractility was also diminished under basal conditions. This observation was unexpected, since PKA basal activity is thought to be low in unstimulated cardiomyocytes, implying additional pathways that mediate the depressive effects of the I-1 mutants on basal contractility.
Interestingly, the two sites appeared equivalent, and no additive effect was observed when both sites were simultaneously phosphorylated. These results raise the possibility that phosphorylations of Ser67 and Thr75 may exert their effects independently from each other. However, it remains unclear whether phosphorylation of both targets occurs simultaneously or whether both sites are maximally phosphorylated in vivo. As such, phosphorylation of I-1 at both sites would be required to elicit maximal response, explaining the nonadditive influence of phospho-Ser67 and phospho-Thr75 observed in the present study.
The poor inhibition of PP1 activity on PKA activation in myocytes expressing phospho-Ser67 and phospho-Thr75 I-1 may be due to the decreased ability of I-1 to become phosphorylated by PKA, as indicated by our in vitro findings. These results are in agreement with a recent report, which showed that phosphorylation of Ser65 and Ser67 altered the ability of I-1 to serve as a PKA substrate in mouse brain tissue (17) .
It has been shown that transgenic mice either lacking or overexpressing PKC-␣ present enhanced or reduced cardiac contractility, respectively. Moreover, modulation of PKC-␣ activity in those mouse models affected phosphorylation of phospholamban (4) . Accordingly, constitutive phosphorylation of I-1 at Ser67 and/or Thr75 was associated with decreased phospholamban phosphorylation at Ser16 and depressed SR Ca 2ϩ uptake rates under PKA activation. Consequently, the mechanical performance of the cardiomyocytes expressing I-1 mutants mirrored SR Ca 2ϩ uptake measurements. Furthermore, PKA activation by forskolin did not improve SERCA2a function or contractility to the same extent as myocytes expressing I-1WT or GFP. Therefore, we postulate that the poor inhibition of PP1 in cardiomyocytes expressing the PKC-phosphorylated I-1 on PKA activation may lead to reduced phospho-Ser16 phospholamban, which impairs SERCA2a function and leads to depressed myocyte contractility. These findings suggest an important cross talk between PKA and PKC through I-1.
Taken together, our data suggest that enhanced PKC signaling in failing hearts may result in increased phosphorylation of I-1 at Ser67 and Thr75. These phosphorylations may work to partially suppress the ␤-adrenergic signaling cascade and consequently reduce the stimulatory effects on contractility through the maintenance of an abnormally enhanced PP1 activity. Thus I-1 appears to regulate cardiac contractility, and targeted regulation of its activity may be beneficial in the deteriorated function of failing hearts.
